1. Arrigo M, Huber LC, Winnik S, Mikulicic F, Guidetti F, Frank M, Flammer AJ, Ruschitzka F. Right ventricular failure: pathophysiology, diagnosis and treatment. Card Fail Rev. 2019;5:140-146.
2. Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, Jais X, Taniguchi Y, O'Connell C, Parent F, Sattler C, Herve P, Simonneau G, Montani D, Humbert M, Adir Y, Sitbon O. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation. 2018;137:693-704.
3. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67-119.
4. Pierre-Yves C, Géraldine PJ, Chahéra K, Christian S, Ségolène T, Jean-Charles G, Bénédicte M, Béatrice G, Anne-Sophie BL, Alfred D, Geneviève D, Marc H, Jean- François M, Jean-François C, Vincent C. Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension. Eur Respir J. 2015;45:139-149.
5. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, Vonk-Noordegraaf A. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58:2511-2519.
6. Melenovsky V, Hwang SJ, Lin G, Redfield MM,Borlaug BA. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3452-3462.
7. Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, Deng M, Dickstein ML, El-Banayosy A, Elliot T, Goldstein DJ, Grady KL, Jones K, Hryniewicz K, John R, Kaan A, Kusne S, Loebe M, Massicotte MP, Moazami N, Mohacsi P, Mooney M, Nelson T, Pagani F, Perry W, Potapov EV, Eduardo RJ, Russell SD, Sorensen EN, Sun B, Strueber M, Mangi AA, Petty MG, Rogers J. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32:157-187.
8. Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res. 2014;115:176-188.
9. Xin Z, Lin G, Lei H, Lue TF, Guo Y. Clinical applications of low-intensity pulsed ultrasound and its potential role in urology. Transl Androl Urol 2016;5:255-266.
10. Xiaoxue J, Oleksandra S, Yufeng L, Shiang Q, Tianlin Y, Wei Z, Jie C. Review of Low- Intensity Pulsed Ultrasound for Therapeutic Applications. IEEE Trans Biomed Eng. 2019;:2704-2718.
11. Hanawa K, Ito K, Aizawa K, Shindo T, Nishimiya K, Hasebe Y, Tuburaya R, Hasegawa H, Yasuda S, Kanai H, Shimokawa H. Low-intensity pulsed ultrasound induces angiogenesis and ameliorates left ventricular dysfunction in a porcine model of chronic myocardial ischemia. PLoS One. 2014;9:e104863.
12. Shindo T, Shimokawa H. Therapeutic angiogenesis with sound waves. Ann Vasc Dis. 2020;13:116-125.
13. Shindo T, Ito K, Ogata T, Hatanaka K, Kurosawa R, Eguchi K, Kagaya Y, Hanawa K, Aizawa K, Shiroto T, Kasukabe S, Miyata S, Taki H, Hasegawa H, Kanai H, Shimokawa H. Low-intensity pulsed ultrasound enhances angiogenesis and ameliorates left ventricular dysfunction in a mouse model of acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2016;36:1220-1229.
14. Ogata T, Ito K, Shindo T, Hatanaka K, Eguchi K, Kurosawa R, Kagaya Y, Monma Y, Ichijo S, Taki H, Kanai H, Shimokawa H. Low-intensity pulsed ultrasound enhances angiogenesis and ameliorates contractile dysfunction of pressure-overloaded heart in mice. PLoS One. 2017;12:e0185555.
15. Monma Y, Shindo T, Eguchi K, Kurosawa R, Kagaya Y, Ikumi Y, Ichijo S, Nakata T, Miyata S, Matsumoto A, Sato H, Miura M, Kanai H, Shimokawa H. Low-intensity pulsed ultrasound ameliorates cardiac diastolic dysfunction in mice. -A possible novel therapy for HFpEF. Cardiovasc Res. 2021;117:1325-1338.
16. Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829-837.
17. Wallerath T, Gath I, Aulitzky WE, Pollock JS, Kleinert H, Forstermann U. Identification of the NO synthase isoforms expressed in human neutrophil granulocytes, megakaryocytes and platelets. Thromb Haemostasis. 1997;77:163-167.
18. Lundberg JO, Gladwin MT, Weitzberg E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov. 2015;14:623-641.
19. Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 2017;219:22-96.
20. Farah C, Michel LYM, Balligand J-L. Nitric oxide signalling in cardiovascular health and disease. Nature Reviews Cardiology. 2018;15:292-316.
21. Emdin M, Aimo A, Castiglione V, Vergaro G, Georgiopoulos G, Saccaro LF, Lombardi CM, Passino C, Cerbai E, Metra M, Senni M. Targeting cyclic guanosine monophosphate to treat heart failure. J Am Coll Cardiol. 2020;76:1795-1807.
22. Park M, Sandner P, Krieg T. cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. Basic Res Cardiol. 2018;113:24.
23. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222.
24. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E, Kass DA. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol. 2009;53:207-215.
25. Nergui S, Fukumoto Y, Zhulanqiqige D, Nakajima S, Shimizu T, Ikeda S, Elias-Al- Mamun M, Shimokawa H. Role of endothelial nitric oxide synthase and collagen metabolism in right ventricular remodeling due to pulmonary hypertension. Circ J. 2014;78:1465-1474.
26. Bisserier M, Pradhan N, Hadri L. Current and emerging therapeutic approaches to pulmonary hypertension. Rev Cardiovasc Med. 2020;21:163-179.
27. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382:1883-1893.
28. Ichijo S, Shindo T, Eguchi K, Monma Y, Nakata T, Morisue Y, Kanai H, Osumi N, Yasuda S, Shimokawa H. Low-intensity pulsed ultrasound therapy promotes recovery from stroke by enhancing angio-neurogenesis in mice in vivo. Sci Rep. 2021;11:4958.
29. X P Yang, Y H Liu, E G Shesely, M Bulagannawar, F Liu, O A Carretero. Endothelial Nitric Oxide Gene Knockout Mice Cardiac Phenotypes and the Effect of Angiotensin- Converting Enzyme Inhibitor on Myocardial Ischemia/Reperfusion Injury. Hypertension. 1999;34:24-30.
30. Arraj M. Lemmer B. Endothelial Nitric Oxide Is Not Involved in Circadian Rhythm Generation of Blood Pressure: Experiments in Wild-Type C57 and eNOS Knock-Out Mice under Light-Dark and Free-Run Condit. Chronobiol Int. 2007;24:1231-40.
31. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson MA, Johnson RJ, Croker B. Diabetic Endothelial Nitric Oxide Synthase Knockout Mice Develop Advanced Diabetic Nephropathy. J Am Soc Nephrol. 2007;18:539-550
32. Le Gouill E, Jimenez M, Binnert C, Jayet PY, Thalmann S, Nicod P, Scherrer U, Vollenweider P. Endothelial nitric oxide synthase (eNOS) knockout mice have defective mitochondrial beta-oxidation. Diabetes. 2007;56:2690-6.
33. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation. 2010 Jun 29;121(25):2747-54.
34. Toba M, Abdallah A, Kealan D O’Neill, Salina G, Matsumoto Y, Oshima K, Abe K, Oka M,IvanFM. Temporal hemodynamic and histological progression in Sugen5416/hypoxia/ normoxia-exposed pulmonary arterial hypertensive rats. Am J Physiol Heart Circ Physiol. 2014;306:243-250.
35. Savai R, Al-Tamari HM, Sedding D, Kojonazarov B, Muecke C, Teske R, Capecchi MR, Weissmann N, Grimminger F, Seeger W, Schermuly RT, Pullamsetti SS. Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. Nat Med. 2014;20:1289-1300.
36. Kohut A, Patel N, Singh H. Comprehensive echocardiographic assessment of the right ventricle in murine models. J Cardiovasc Ultrasound. 2016;24:229-238.
37. Mendes-Ferreira P, Maia-Rocha C, Adao R, Mendes MJ, Santos-Ribeiro D, Alves BS, Cerqueira RJ, Castro-Chaves P, Lourenco AP, De Keulenaer GW, Leite-Moreira AF, Bras-Silva C. Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. Cardiovasc Res. 2016;109:44-54.
38. Yin X, Wang L, Qin G, Luo H, Liu X, Zhang F, Ye Z, Zhang J, Wang E. Rats with chronic, stable pulmonary hypertension tolerate low dose sevoflurane inhalation as well as normal rats do. PLoS One. 2016;11:e0154154.
39. Boehm M, Lawrie A, Wilhelm J, Ghofrani HA, Grimminger F, Weissmann N, Seeger W, Schermuly RT, Kojonazarov B. Maintained right ventricular pressure overload induces ventricular-arterial decoupling in mice. Exp Physiol. 2017;102:180-189.
40. Ryan JJ, Marsboom G, Fang YH, Toth PT, Morrow E, Luo N, Piao L, Hong Z, Ericson K, Zhang HJ, Han M, Haney CR, Chen CT, Sharp WW, Archer SL. PGC1a-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;187:865-878.
41. Fish R, Danneman PJ, Brown M, Karas A. Anesthesia and Analgesia in Laboratory Animals. Academic Press, 2nd ed, 2008.
42. Miura M, Wakayama Y, Endoh H, Nakano M, Sugai Y, Hirose M, Ter Keurs HE, Shimokawa H. Spatial non-uniformity of excitation-contraction coupling can enhance arrhythmogenic-delayed afterdepolarizations in rat cardiac muscle. Cardiovasc Res. 2008;80:55-61.
43. Miura M, Nishio T, Hattori T, Murai N, Stuyvers BD, Shindoh C, Boyden PA. Effect of nonuniform muscle contraction on sustainability and frequency of triggered arrhythmias in rat cardiac muscle. Circulation. 2010;121:2711-2717.
44. Miura M, Handoh T, Taguchi Y, Hasegawa T, Takahashi Y, Morita N, Matsumoto A, Shindoh C, Sato H. Transient elevation of glucose increases arrhythmia susceptibility in non-diabetic rat trabeculae with non-uniform contraction. Circ J. 2020;84:551-558.
45. Edward GS, Maeda N, HS. Kim, Kaushik MD,John HK, Victor EL, Paula AS, William CS, Oliver S. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Nat Acad Sci USA. 1996;93:13176-13181.
46. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol. 2007;42:271-279.
47. Matsubara M, Hayashi N, Jing T, Titani K. Regulation of endothelial nitric oxide synthase by protein kinase C. J Biochem. 2003;133:773-781.
48. Ferreira JC, Brum PC, Mochly-Rosen D. IIPKC and PKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51:479-484.
49. Reddy S, Bernstein D. Molecular Mechanisms of Right Ventricular Failure. Circulation. 2015;132:1734-1742.
50. Power AS, Hickey AJ, Crossman DJ, Loiselle DS, Ward ML. Calcium mishandling impairs contraction in right ventricular hypertrophy prior to overt heart failure. Pflugers Arch. 2018;470:1115-1126.
51. Rain S, Bos Dda S, Handoko ML, Westerhof N, Stienen G, Ottenheijm C, Goebel M, Dorfmuller P, Guignabert C, Humbert M, ogaard HJ, Remedios CD, Saripalli C, Hidalgo CG, Granzier HL, Vonk-Noordegraaf A, van der Velden J, de Man FS. Protein changes contributing to right ventricular cardiomyocyte diastolic dysfunction in pulmonary arterial hypertension. J Am Heart Assoc. 2014;3:e000716.
52. Frantz S, Klaiber M, Baba HA, Oberwinkler H, Volker K, Gabetaner B, Bayer B, Abebetaer M, Schuh K, Feil R, Hofmann F, Kuhn M. Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP- dependent protein kinase I. Eur Heart J. 2013;34:1233-1244.
53. Li H, Witte K, August M, Brausch I, Godtel-Armbrust U, Habermeier A, Closs EI, Oelze M, Munzel T, Forstermann U. Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol. 2006;47:2536-2544.
54. Ikeda S, Satoh K, Kikuchi N, Miyata S, Suzuki K, Omura J, Shimizu T, Kobayashi K, Kobayashi K, Fukumoto Y, Sakata Y, Shimokawa H. Crucial role of rho-kinase in pressure overload-induced right ventricular hypertrophy and dysfunction in mice. Arterioscler Thromb Vasc Biol. 2014;34:1260-1271.
55. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597-601.
56. Urashima T, Zhao M, Wagner R, Fajardo G, Farahani S, Quertermous T, Bernstein D. Molecular and physiological characterization of RV remodeling in a murinemodel of pulmonary stenosis. Am J Physiol Heart Circ Physiol. 2008,295:1351-1368.
57. Razny U, Kiec-Wilk B, Wator L, Polus A, Dyduch G, Solnica B, Malecki M, Tomaszewska R, Cooke JP, Dembinska-Kiec A. Increased nitric oxide availability attenuates high fat diet metabolic alterations and gene expression associated with insulin resistance. Cardiovasc Diabetol. 2011;10:68.
58. Dewachter L, Dewachter C. Inflammation in right ventricular failure: Does it matter? Front Physiol. 2018;9:1056.
論文の公開元へ
